TW200502252A - Formulations of modified antibodies and methods of making the same - Google Patents

Formulations of modified antibodies and methods of making the same

Info

Publication number
TW200502252A
TW200502252A TW092123282A TW92123282A TW200502252A TW 200502252 A TW200502252 A TW 200502252A TW 092123282 A TW092123282 A TW 092123282A TW 92123282 A TW92123282 A TW 92123282A TW 200502252 A TW200502252 A TW 200502252A
Authority
TW
Taiwan
Prior art keywords
modified antibody
formulations
modified
methods
present
Prior art date
Application number
TW092123282A
Other languages
English (en)
Inventor
Lavinia M Lewis
Hong Qi
Robert E Johnson
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TW200502252A publication Critical patent/TW200502252A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW092123282A 2002-08-28 2003-08-25 Formulations of modified antibodies and methods of making the same TW200502252A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40641202P 2002-08-28 2002-08-28

Publications (1)

Publication Number Publication Date
TW200502252A true TW200502252A (en) 2005-01-16

Family

ID=31978297

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092123282A TW200502252A (en) 2002-08-28 2003-08-25 Formulations of modified antibodies and methods of making the same

Country Status (5)

Country Link
US (1) US20040247588A1 (zh)
AR (1) AR041068A1 (zh)
AU (1) AU2003276844A1 (zh)
TW (1) TW200502252A (zh)
WO (1) WO2004019860A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2316422A1 (en) * 2007-11-12 2011-05-04 Novartis AG Liquid compositions comprising valsartan
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3855197A (en) * 1969-05-20 1974-12-17 Cassenne Lab Sa Glycoproteins extracted from microorganisms
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4654407A (en) * 1985-08-02 1987-03-31 Amoco Corporation Aromatic bismaleimide and prepreg resin therefrom
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5795697A (en) * 1996-07-04 1998-08-18 Agfa-Gevart, N.V. Imaging element for making an improved printing plate according to the silver salt diffusion transfer process
US5998061A (en) * 1997-10-20 1999-12-07 Micron Communications, Inc. Thin-profile battery electrode connection members, button-type battery electrode connection members, thin-profile battery constructions and button-type battery constructions
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
JP3743495B2 (ja) * 2000-07-10 2006-02-08 信越化学工業株式会社 硬化性フルオロポリエーテルゴム組成物

Also Published As

Publication number Publication date
WO2004019860A3 (en) 2004-07-22
AU2003276844A1 (en) 2004-03-19
WO2004019860A2 (en) 2004-03-11
AR041068A1 (es) 2005-04-27
AU2003276844A8 (en) 2004-03-19
US20040247588A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
DK1151007T3 (da) Fremgangsmåde til fremstilling af et præparat baseret på fibrinogen og fibronectin samt proteinsammensætninger fremstillet derved
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
ATE553125T1 (de) Herstellung eines multimeren proteins durch zellfusionsverfahren
ATE407987T1 (de) Neue mesogene, verfahren zu deren herstellung und verwendung
DE69628148D1 (de) Verfahren zur herstellung eines proteins
DE68921364D1 (de) Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
ATE404588T1 (de) Verfahren zur herstellung von chondroitinsulfaten aus k4-polysaccharid und so hergestellte produkte
TW200502252A (en) Formulations of modified antibodies and methods of making the same
DE60125218D1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
DE59810762D1 (de) Verfahren zur herstellung von wasserlöslichen bzw. wasserquellbaren polymerisaten mit sehr niedrigem restmonomergehalt, danach hergestellte produkte und deren verwendung
ATE369442T1 (de) In vitro evolution von nukleinsäuren und kodierten polypeptiden
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ATE335750T1 (de) Verfahren zur herstellung von organosilylalkylpolysulfanen
ATE403005T1 (de) Rekombinantes mva und verfahren zur erzeugung davon
ATE495196T1 (de) Verfahren zur herstellung eines peptid-träger- konjugats mit hoher immunogenizität
DE60226612D1 (de) Autologe t-zell-vakzinmaterialien und verfahren
DE60038281D1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
PL373004A1 (en) Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
ATE443709T1 (de) Verfahren zur herstellung von 9,10-dihydro-9-oxa- 10-organyl-oxyphosphaphenanthren-10-oxid oder - thion und an den phenylgruppen substituierten derivativen desselben
ATE525418T1 (de) Verfahren zur herstellung von silikon-organischen kopolymeren
ATE319837T1 (de) Verfahren zur herstellung von rekombinantem trypsin
DE50301697D1 (de) Verfahren zur herstellung von polyetheralkoholen
ATE251121T1 (de) Verfahren zur herstellung von 1,3,6- hexantricarbonitril